To review data on the use of tamoxifen for primary prevention of breast cancer.
DATA SOURCES:
A literature search was performed through MEDLINE (1992–May 2002) using the key words tamoxifen, breast cancer, and prevention.
DATA SYNTHESIS:
Breast cancer is the most common malignancy detected in American women. Attempts to reduce morbidity and mortality include early detection programs and chemoprevention. Clinical trials of tamoxifen for reduction of breast cancer risk are reviewed.
CONCLUSIONS:
Tamoxifen may reduce the risk of primary breast cancer in women at increased risk. The benefit of tamoxifen in women who are not at risk is uncertain. The risks of developing thromboembolic disorders or endometrial cancer must be considered before tamoxifen is prescribed. Women should be given all of the information about the benefits and risks of tamoxifen use so that they can make an informed decision based on the best data available.
Package insert. Nolvadex (tamoxifen citrate). Wilmington, DE: AstraZenica Pharmaceuticals, May 2002.
3.
GailMH, BrintonLA, ByarDP, CorleDK, GreenSB, SchairerC, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst1989; 81: 1879-86.
4.
FisherB, CostantinoJP, WickerhamDL, RedmondCK, KavanahM, CroninWM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst1998; 90: 1371-88.
5.
VeronesiU, MaisonneuveP, CostaA, SacchiniV, MaltoniC, RobertsonC, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomised women. Lancet1998; 352: 93-7.
6.
PowlesT, EelesR, AshleyS, EastonD, ChangJ, DowsettM, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet1998; 352: 98-101.
7.
VeronesiU, MaisonneuveP, SacchiniV, RotmenszN, BoyleP.Tamoxifen for breast cancer among hysterectomised women. Lancet2002; 359: 1122-4.
8.
Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet1997; 350: 1047-59.
9.
PritchardKI. Is tamoxifen effective in prevention of breast cancer?Lancet1998; 352: 80-1.
10.
CostantinoJP, VogelVG. Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: an alternative view. Clin Breast Cancer2001; 2: 41-6.
11.
FisherB.National Surgical Adjuvant Breast and Bowel Project breast cancer prevention trial: a reflective commentary. J Clin Oncol1999; 17: 1632-9.
12.
FisherB, CostantinoJP, RedmondCK, FisherER, WickerhamDL, CroninWM, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst1994; 86: 527-37.
13.
BarakatRR, WongG, CurtinJP, VlamisV, HoskinsWJ. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gy-necol Oncol1994; 55: 164-8.
14.
FornanderT, HellstromA-C, MobergerB.Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst1993; 85: 1850-5.
15.
CurtisRE, BoiceJD, ShrinerDA, HankeyBF, FraumeniJFJr. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst1996; 88: 832-4.
16.
CuencaRE, GiachinoJ, ArredondoMA, HemplingR, EdgeSE. Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use. Cancer1996; 77: 2058-63.
17.
AssikisVJ, JordanVC. Tamoxifen and endometrial cancer: from experiment to patient. Recent Res Cancer Res1996; 140: 61-71.
18.
MagriplesU, NaftolinF, SchwartzPE, CarcangiuML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol1993; 11: 485-90.
19.
MignotteH, LassetC, BonadonaV, LesurA, LuporsiE, RodierJ-F, et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case–control study. Int J Cancer1998; 76: 325-30.
20.
BergmanL, BeelenMLR, GalleeMPW, HollemaH, BenraadtJ, van LeeuwenFE, et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet2000; 356: 881-7.
21.
GelmonK.One step forward or one step back with tamoxifen?Lancet2000; 356: 868-9.
22.
BernsteinL, DeapenD, CerhanJR, SchwartzSM, LiffJ, McGann-MaloneyE, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst1999; 91: 1654-62.
23.
StearnsV, GelmannEP. Does tamoxifen cause cancer in humans?J Clin Oncol1998; 16: 779-92.
24.
GailMH, CostantinoJ P, BryantJ, CroyleR, FreedmanL, HelzlsouerK, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst1999; 91: 1829-46.
25.
TaylorAL, Adams-CampbellLL, WrightJTJr. Risk/benefit assessment of tamoxifen to prevent breast cancer — still a work in progress?J Natl Cancer Inst1999; 91: 1792-3.
26.
BertelliG, VenturiniM, Del MastroL, GarroneO, CossoM, GustavinoC, et al. Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res Treat1998; 47: 41-6.
27.
ACOG committee opinion: tamoxifen and endometrial cancer. Int J Gynaecol Obstet2001; 73: 77-9.
28.
HershmanD, SundararajanV, JacobsenJS, HeitjanDF, NeugutAI, GrannVR. Outcomes of tamoxifen chemoprevention for breast cancer in very high risk women: a cost-effectiveness analysis. J Clin Oncol2001; 20: 9–16.
29.
GoelV.Tamoxifen and breast cancer prevention: what should you tell your patients?Can Med Assoc J1998; 158: 1615-7.
30.
ChlebowskiRT, CollyarDE, SomerfieldMR, PfisterDG. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol1999; 17: 1939-55.
